| This week's sponsor is Novella. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Thursday, December 14, 2017 Teva’s layoffs and cost cuts are here—and they're far larger and deeper than reports predicted. The company intends to ax 14,000 jobs, more than one-fourth of its worldwide workforce, while shutting down plants, R&D facilities and offices around the globe. |
|
|
Top Stories Of The Week Friday, December 8, 2017 Denali Therapeutics has raised $250 million. The IPO, the biggest biotech listing of the year, sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials. Monday, December 11, 2017 Patients with highly advanced multiple myeloma have seen spectacular results with Bluebird Bio and Celgene’s CAR-T therapy bb2121; the disease was pushed into remission in more than half of those treated. Tuesday, December 12, 2017 Based on data from Australia, which already had its flu season, scientists warn that this season’s flu shot might be only 10% effective. And the egg-based vaccine production process might be the reason for such a low level of protection, a new NEJM piece suggests. Friday, December 8, 2017 A Salk Institute team created a form of CRISPR/Cas9 that activates specific genes without making breaks in the DNA, which can cut down on harmful side effects. Tuesday, December 12, 2017 Johnson & Johnson has found plenty of success moving Darzalex earlier and earlier into multiple myeloma therapy, and it now boasts data that could help it win a coveted spot in first-line treatment. Monday, December 11, 2017 When we were compiling this year’s crop of Fierce 15 companies, some clear themes stood out. Genomics. Bioelectronics. Artificial intelligence. But while multiple companies are working to improve the use of these technologies, there runs a deeper current: making care more accessible. Tuesday, December 12, 2017 Sanofi is recalling a lot of its injected gel for treating arthritis in knees in the U.S. which has tested positive for microbial contamination and been linked to some adverse events. Wednesday, December 13, 2017 Johnson & Johnson’s Janssen Oncology unit today unveiled a new website that creates big expectations with its very name. As one Janssen manager said, “If you put something on Cancer.com, it had better be good." Wednesday, December 13, 2017 The Parexel-Microsoft partnership announced in October has reaped its first crop: Perceptive Cloud, a cloud platform with Parexel’s informatics solutions now built on the enhanced cloud infrastructure of Microsoft Azure. Resources Presented By: Patheon When a biologics company prepares to launch a new product, it must forecast the capacity it will need. Download Patheon's whitepaper to learn how to mitigate risks by developing a manufacturing strategy that will accommodate a forecast range and allow you to adapt as better data becomes available. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. | 